Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer

Oncology Today with Dr Neil Love

English - March 11, 2024 15:00 - 37 minutes - 34.4 MB
Medicine Health & Fitness Science dr neil love research to practice oncology today oncology cme Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series

Next Episode: Virtual Case Library: Metastatic Urothelial Bladder Cancer

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayOralSERDsmBC23).

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

CME information and select publications here.